Skip to main content
ZELIRA THERAPEUTICS LIMITED logo

ZELIRA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ZLD ISIN · AU000000ZLD1 ASX Manufacturing
Open in API
Filings indexed 974 across all filing types
Latest filing 2026-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX ZLD

About ZELIRA THERAPEUTICS LIMITED

https://zeliratx.com/

Zelira Therapeutics Limited is a biopharmaceutical company focused on the research, development, and commercialization of clinically validated cannabinoid-based medicines. The company utilizes a data-driven approach to develop therapeutic products targeting conditions such as insomnia, chronic pain, and autism. Its portfolio includes Zenivol, a clinically validated treatment for insomnia, and the HOPE range of products designed for patients with autism. Zelira emphasizes a clinical trial-led strategy to establish the safety and efficacy of its formulations, aiming to provide healthcare professionals and patients with evidence-based cannabinoid treatments. The company also explores dermatological applications and maintains a pipeline of proprietary formulations undergoing rigorous scientific evaluation to address unmet medical needs in global markets.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 688.0KB
Interim / Quarterly Report Classification · 85% confidence The document is an ASX Announcement presenting Zelira’s Quarterly Activities Report and Appendix 4C cash flow statement for Q3 FY2026. It includes substantive financial data (quarterly cash flows, operational highlights, strategic outlook) rather than merely announcing publication of a separate report. Under the filing definitions, this constitutes an Interim/Quarterly Report covering a period shorter than a full fiscal year with actual financial statements and analysis. Q3 2026
2026-04-28 English
Director Loan 4 pages 1.9MB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 10 March 2026 regarding a Director Loan from a Non-Executive Director to the company. It details the terms of the loan note, including the loan amount, interest, maturity, and potential conversion into shares subject to shareholder approval. The document also includes background information about the company and its business activities. There are no financial statements, comprehensive financial data, or detailed financial performance analysis present. The document primarily serves as a disclosure of a financing arrangement involving a director, which is a capital/financing update rather than a full financial report or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7290 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2026-03-09 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 665.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report for Q2 FY2026' and includes detailed operational highlights, fundraising updates, R&D tax incentive information, director loans, and a financial snapshot with cash flow statements. It also contains an Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules. The content includes substantive financial data and analysis for the quarter ended 31 December 2025, indicating it is a comprehensive interim financial report rather than a brief announcement or a certification. The presence of detailed financial statements and operational commentary aligns with the definition of an Interim / Quarterly Report (IR). Q2 2026
2026-01-28 English
Transformative US$33M Fundraising into Zeliras HOPE 1 SPV 6 pages 2.1MB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement about a significant fundraising event involving Zelira Therapeutics and ThirdGate Capital for a special purpose vehicle (SPV) named HOPE® 1 SPV. It includes specifics about the amount raised, equity distribution, clinical trial plans, FDA regulatory pathway, management and board structure of the SPV, and future steps related to the clinical development of the HOPE® 1 product. The content focuses on capital raising, investment terms, and financing structure rather than financial results, earnings, or regulatory filings unrelated to financing. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. The document is not a simple announcement of a report publication but a substantive update on financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-01-15 English
Notification regarding unquoted securities - ZLD 5 pages 16.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted convertible notes by Zelira Therapeutics Limited. It includes specifics such as the number of securities issued, issue date, issue price, and currency. The document is a formal notification of a securities issuance event, referencing a previous Appendix 3B announcement. It does not contain financial statements, management discussion, or earnings data. It is not a report but an announcement of a capital change event related to securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (4821 characters) and content confirm it is a substantive announcement, not merely a report publication notice or regulatory filing.
2025-12-03 English
Change of Director's Interest Notice x2 4 pages 320.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the number of shares and convertible notes acquired, dates of changes, and nature of changes. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is 7980 characters, sufficient to contain detailed transaction information. Therefore, the correct classification is DIRS (Director's Dealing).
2025-12-03 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.